Rigerimod (IPP-201101, Lupuzor) is a polypeptide corresponding to the sequence 131-151 of the 70k snRNP protein with a serine phosphorylated in position 140. [1]
It gave encouraging results in a phase IIb trial for severe lupus. [1] Another phase IIb trial has started recruiting in the US. [2]
References
- ^ a b http://www.medicalnewstoday.com/articles/171853.php 23 Nov 2009
- ^ "Cephalon, ImmuPharma license partner for Rigerimod (Lupuzor) initiates critical steps in its development program". Archived from the original on 2011-09-10. Retrieved 2010-06-28.
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
Rigerimod (IPP-201101, Lupuzor) is a polypeptide corresponding to the sequence 131-151 of the 70k snRNP protein with a serine phosphorylated in position 140. [1]
It gave encouraging results in a phase IIb trial for severe lupus. [1] Another phase IIb trial has started recruiting in the US. [2]
References
- ^ a b http://www.medicalnewstoday.com/articles/171853.php 23 Nov 2009
- ^ "Cephalon, ImmuPharma license partner for Rigerimod (Lupuzor) initiates critical steps in its development program". Archived from the original on 2011-09-10. Retrieved 2010-06-28.
|
| This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |